Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways.
The TNF receptor fusion protein, Ro 45-2081, inhibited allergic and non-allergic inflammatory responses in the airways. Treatment of sensitized guinea-pigs with Ro 45-2081 reduced allergen-induced influx of inflammatory cells into the lungs, abolished edema formation and inhibited hyperreactivity to substance P. Administration of Ro 45-2081 after allergen challenge reversed the influx of inflammatory cells into the lungs. Sephadex-induced neutrophil influx into the lungs of rats was also blocked by Ro 45-2081. The effects of Ro 45-2081 suggest that inhibitors of TNF may have potential as therapeutics for inflammatory diseases in the lung.
Gater
P R
PR
Hoffmann-La Roche Inc., Nutley, NJ 07042, USA.
Renzetti
L M
LM
D000818:Animals; D006168:Guinea Pigs; D007143:Immunoglobulin Heavy Chains / Q000627:therapeutic use*; D007142:Immunoglobulin gamma-Chains; D007249:Inflammation / Q000517:prevention & control*; D008171:Lung Diseases / Q000517:prevention & control*; D008297:Male; D011654:Pulmonary Edema / Q000517:prevention & control; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012130:Respiratory Hypersensitivity / Q000276:immunology / Q000517:prevention & control*; D013373:Substance P / Q000276:immunology
D007143:Immunoglobulin Heavy Chains; D007142:Immunoglobulin gamma-Chains; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D013373:Substance P; C099374:Ro 45-2081